Suchergebnis | Hamburg Open Science

Facetten

6 Einträge gefunden

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
2018 - Forschungsinformationssystem des UKE
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
1. Möbus, V
2. Jackisch, C
3. Lück, H J
4. du Bois, A
5. Thomssen, C
6. Kuhn, W
7. Nitz, U
2018 - Forschungsinformationssystem des UKE
German Adjuvant Intergroup Node-positive Study (GAIN):a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
2017 - Forschungsinformationssystem des UKE
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
2014 - Forschungsinformationssystem des UKE
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
2012 - Forschungsinformationssystem des UKE
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
2011 - Forschungsinformationssystem des UKE